In vitro to clinical translational pharmacokinetic/pharmacodynamic modeling of doxorubicin (dox) and dexrazoxane (dex) interactions: safety assessment and optimization

HIGHLIGHTS

• who: Hardik Mody from the Center for PharmacometricsUniversity of have published the paper: In vitro to clinical translational pharmacokinetic/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization, in the Journal: Scientific Reports Scientific Reports
• what: To summarize, we have developed a proof-of-concept cell-based TD model which can serve as a platform to optimize DOX and DEX combinations to counteract DIC.
• future: Both approaches have limitations and further studies are required to better optimize the two approaches in combination for maximal | 133100 | 7 Vol.(0123456789) | Vol . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.